Biophytis (EPA:ALBPS) | WebDisclosure

Basculer en Français

10368	Companies
216029	Keywords
145754	Articles
114397	Press releases

Home
Companies
Biophytis

PRESS RELEASE

published on 06/12/2024 at 10:11, 1 year 10 months ago

Biophytis annonce le succès du transfert industriel de production de BIO101 (20-hydroxyecdysone) par son prestataire Seqens
Biophytis annonce le succès du transfert industriel de production de BIO101 (20-hydroxyecdysone) par son prestataire Seqens. La société se focalise sur le traitement de maladies liées à l'âge, notamment la Dystrophie Musculaire de Duchenne

Biophytis BIO101 Seqens Transfert Industriel DMD
PRESS RELEASE

published on 06/12/2024 at 10:11, 1 year 10 months ago

Biophytis announces the successful industrial transfer of BIO101 (20-hydroxyecdysone) production by its service provider Seqens
Biophytis successfully transfers BIO101 (20-hydroxyecdysone) production to industrial scale with Seqens, enhancing therapeutic solutions for Duchenne Muscular Dystrophy patients

Biophytis Duchenne Muscular Dystrophy BIO101 Seqens 20-hydroxyecdysone
BRIEF

published on 06/12/2024 at 07:05, 1 year 10 months ago

Biophytis annonce le succès du transfert de production de BIO101 par Seqens

Biophytis Dystrophie Musculaire De Duchenne BIO101 Seqens Production Industrielle
BRIEF

published on 06/12/2024 at 07:05, 1 year 10 months ago

Biophytis Announces Successful Industrial Transfer of BIO101 Production by Seqens

Biophytis Clinical Trial Duchenne Muscular Dystrophy BIO101 Seqens
REGULATED PRESS RELEASE

published on 06/12/2024 at 07:00, 1 year 10 months ago

Biophytis annonce le succès du transfert industriel de production de BIO101 (20-hydroxyecdysone) par son prestataire Seqens
Biophytis annonce le succès du transfert industriel de production de BIO101 par Seqens, renforçant ainsi son programme de développement clinique pour traiter la Dystrophie Musculaire de Duchenne (DMD)

Biophytis Dystrophie Musculaire De Duchenne BIO101 Seqens Transfert Industriel
REGULATED PRESS RELEASE

published on 06/12/2024 at 07:00, 1 year 10 months ago

Biophytis announces the successful industrial transfer of BIO101 (20-hydroxyecdysone) production by its service provider Seqens
Biophytis announces successful industrial transfer of BIO101 (20-hydroxyecdysone) production by Seqens for DMD treatment. Collaboration strengthens therapeutic solutions and accelerates clinical programs

Biophytis Clinical Development Duchenne Muscular Dystrophy BIO101 Seqens
BRIEF

published on 06/10/2024 at 08:23, 1 year 10 months ago

Biophytis dépose une demande d'IND pour une étude de phase 2 dans l'obésité

Biophytis Phase 2 BIO101 Obésité IND
BRIEF

published on 06/10/2024 at 08:23, 1 year 10 months ago

Biophytis Files IND Application for Phase 2 Obesity Study with US FDA

FDA Biophytis Clinical Study Obesity IND Application
BRIEF

published on 06/10/2024 at 08:21, 1 year 10 months ago

Biophytis dépose une demande d'IND pour une étude de phase 2 dans l'obésité

FDA Biophytis Phase 2 BIO101 Obésité
BRIEF

published on 06/10/2024 at 08:21, 1 year 10 months ago

Biophytis files IND application for phase 2 study in obesity

FDA Biophytis Phase 2 BIO101 Obesity

Accesswire

Published on 05/08/2026 at 01:50, 7 hours 37 minutes ago

Apex Critical Metals Announces Grant of Stock Options and RSUs
Published on 05/08/2026 at 00:45, 8 hours 42 minutes ago

Route1 Announces First Quarter 2026 Financial Results Notification
Published on 05/08/2026 at 00:00, 9 hours 27 minutes ago

Redwood AI Approved to Receive National Research Council of Canada Funding for its Q-SAFE Chemical Screening Project for Defence and Security Applications
Published on 05/07/2026 at 23:30, 9 hours 57 minutes ago

Faraday Copper Reports First Quarter 2026 Financial Results
Published on 05/07/2026 at 23:15, 10 hours 12 minutes ago

BULGOLD Adopts Semi-Annual Financial Reporting

View all ACCESSWIRE

EQS Group

Published on 05/08/2026 at 09:01, 26 minutes ago

Original-Research: Scandinavian Astor Group AB (von NuWays AG): BUY
Published on 05/08/2026 at 09:01, 26 minutes ago

Original-Research: Westwing Group SE (von NuWays AG): BUY
Published on 05/08/2026 at 09:00, 27 minutes ago

Original-Research: Deutsche Beteiligungs AG (von NuWays AG): BUY
Published on 05/08/2026 at 09:00, 27 minutes ago

Original-Research: DEMIRE AG (von NuWays AG): BUY
Published on 05/08/2026 at 09:00, 27 minutes ago

Original-Research: GFT Technologies SE (von NuWays AG): BUY

Les Echos

Published on 05/07/2026 at 19:15, 14 hours 12 minutes ago

2026 Annual General Meeting: approval of all resolutions submitted to the Meeting
Published on 05/07/2026 at 19:15, 14 hours 12 minutes ago

Assemblée Générale annuelle 2026 : approbation de l’ensemble des résolutions soumises au vote
Published on 05/07/2026 at 19:06, 14 hours 21 minutes ago

Disclosure of Share Capital and Voting Rights as of April 30, 2026
Published on 05/07/2026 at 19:06, 14 hours 21 minutes ago

Déclaration du nombre d’actions et droits de vote au 30 avril 2026
Published on 05/07/2026 at 19:00, 14 hours 27 minutes ago

ALTAREIT - INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL

View all LES ECHOS COMFI WIRE